AI Engines For more Details: Perplexity Kagi Labs You
Neuropathy Management: Benfotiamine is often used as a supplement to help manage peripheral neuropathy, a common complication of diabetes. Peripheral neuropathy is characterized by nerve damage in the peripheral nervous system, leading to symptoms such as numbness, tingling, and pain in the extremities. Benfotiamine may help alleviate these symptoms by supporting nerve health and function.
Antioxidant Properties: Benfotiamine exhibits antioxidant properties, which may help reduce oxidative stress and inflammation associated with various chronic conditions, including diabetes, neurodegenerative diseases, and cardiovascular disorders. By scavenging free radicals and inhibiting oxidative damage, benfotiamine may contribute to overall health and well-being.
Advanced Glycation End Products (AGEs) Inhibition: Benfotiamine has been shown to inhibit the formation of advanced glycation end products (AGEs), which are harmful compounds formed when sugars react with proteins in the body. Excessive AGEs can contribute to tissue damage and complications associated with diabetes, including neuropathy, nephropathy, and ret
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 1.6 | 0.3 | 4.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 1.2 | 0.5 | 1.4 |
| Allergies | 1.7 | 1.8 | -0.06 |
| Allergy to milk products | 1 | 1.2 | -0.2 |
| Alzheimer's disease | 2.2 | 2.7 | -0.23 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 0.4 | 2 |
| Ankylosing spondylitis | 1.6 | 1.2 | 0.33 |
| Anorexia Nervosa | 0.6 | 1.4 | -1.33 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.3 | -2 |
| Asthma | 1.9 | 1.1 | 0.73 |
| Atherosclerosis | 1.3 | 0.6 | 1.17 |
| Atrial fibrillation | 1.5 | 1.5 | 0 |
| Autism | 2.7 | 3.4 | -0.26 |
| Autoimmune Disease | 0.9 | 0.8 | 0.13 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.2 | 0.2 | |
| Bipolar Disorder | 1.5 | 1.1 | 0.36 |
| Brain Trauma | 0.3 | 1.4 | -3.67 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.3 | 0.5 | -0.67 |
| Carcinoma | 2.1 | 0.9 | 1.33 |
| Celiac Disease | 0.4 | 1.6 | -3 |
| Cerebral Palsy | 0.6 | 1.1 | -0.83 |
| Chronic Fatigue Syndrome | 2 | 1.5 | 0.33 |
| Chronic Kidney Disease | 0.9 | 1.4 | -0.56 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 1.4 | -1 |
| Chronic Urticaria (Hives) | 0.7 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.8 | -0.14 |
| Cognitive Function | 0.9 | 0.8 | 0.13 |
| Colorectal Cancer | 2.5 | 1.2 | 1.08 |
| Constipation | 1.5 | 0.5 | 2 |
| Coronary artery disease | 1 | 1.1 | -0.1 |
| COVID-19 | 2 | 2.4 | -0.2 |
| Crohn's Disease | 3.1 | 2.3 | 0.35 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.7 | 1.1 | -0.57 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 1.1 | 1.1 | 0 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 3.5 | 3 | 0.17 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.9 | 0.3 | 2 |
| Endometriosis | 1.6 | 1.5 | 0.07 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 1.6 | 0.6 | 1.67 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 0.8 | 0.8 | 0 |
| Functional constipation / chronic idiopathic constipation | 2.3 | 1.7 | 0.35 |
| gallstone disease (gsd) | 1 | 1.1 | -0.1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.3 | 0.33 |
| Generalized anxiety disorder | 1.6 | 1 | 0.6 |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 0.9 | 1.7 | -0.89 |
| Gulf War Syndrome | 0.3 | 0.3 | 0 |
| Halitosis | 0.7 | 0.7 | |
| Hashimoto's thyroiditis | 1.7 | 1.2 | 0.42 |
| Heart Failure | 1.7 | 1.1 | 0.55 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.6 | 0.6 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
| hyperglycemia | 0.7 | 0.6 | 0.17 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.8 | 2.2 | -0.22 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 1.3 | 0.3 | 3.33 |
| IgA nephropathy (IgAN) | 0.9 | 0.9 | 0 |
| Inflammatory Bowel Disease | 1.7 | 3.2 | -0.88 |
| Insomnia | 0.6 | 1.4 | -1.33 |
| Intelligence | 0.7 | 0.7 | |
| Intracranial aneurysms | 0.9 | 0.3 | 2 |
| Irritable Bowel Syndrome | 2.2 | 2 | 0.1 |
| ischemic stroke | 1.1 | 1.4 | -0.27 |
| Liver Cirrhosis | 3 | 2.4 | 0.25 |
| Long COVID | 2.1 | 3.3 | -0.57 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 0.3 | 2 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.7 | 0.9 | -0.29 |
| ME/CFS with IBS | 0.1 | 0.8 | -7 |
| ME/CFS without IBS | 0.6 | -0.6 | |
| Menopause | 0.2 | 0.5 | -1.5 |
| Metabolic Syndrome | 3.1 | 2.8 | 0.11 |
| Mood Disorders | 3.4 | 2.9 | 0.17 |
| Multiple Sclerosis | 1.9 | 1.8 | 0.06 |
| Multiple system atrophy (MSA) | 0.6 | -0.6 | |
| myasthenia gravis | 0.6 | 0.5 | 0.2 |
| neuropathic pain | 1.5 | -1.5 | |
| Neuropathy (all types) | 1.1 | -1.1 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 2.1 | 0.14 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 3.6 | 2.9 | 0.24 |
| obsessive-compulsive disorder | 1.9 | 0.9 | 1.11 |
| Osteoarthritis | 0.9 | 0.9 | 0 |
| Osteoporosis | 1.7 | 0.3 | 4.67 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 3 | 3.3 | -0.1 |
| Polycystic ovary syndrome | 3.2 | 2.3 | 0.39 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.6 | 0.6 | 0 |
| Psoriasis | 0.7 | 1.1 | -0.57 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.7 | 1.7 | 1.18 |
| Rosacea | 0.6 | 0.5 | 0.2 |
| Schizophrenia | 2.1 | 2 | 0.05 |
| scoliosis | 0.4 | 0.6 | -0.5 |
| Sjögren syndrome | 0.6 | 0.6 | 0 |
| Sleep Apnea | 1.5 | 1.4 | 0.07 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.3 | 1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1 | 0.1 | 9 |
| Stress / posttraumatic stress disorder | 1.5 | 1.4 | 0.07 |
| Systemic Lupus Erythematosus | 1.8 | 1.8 | 0 |
| Tic Disorder | 0.3 | 0.3 | 0 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.8 | 2.2 | -0.22 |
| Type 2 Diabetes | 3.1 | 2.5 | 0.24 |
| Ulcerative colitis | 1.7 | 2.1 | -0.24 |
| Unhealthy Ageing | 1.4 | 1.1 | 0.27 |
| Vitiligo | 1.2 | 0.5 | 1.4 |
